Adjuvant Pembrolizumab After Nephrectomy for High-Risk Clear-Cell RCC
Adjuvant pembrolizumab is strongly recommended after nephrectomy for patients with high-risk clear-cell renal cell carcinoma, including those with pathologic stage T3/T4, N+, or grade 3-4 disease. 1
Evidence Basis
The 2025 European Association of Urology guidelines now issue a strong recommendation for adjuvant pembrolizumab based on mature overall survival data from the KEYNOTE-564 trial. This represents an upgrade from the previous weak recommendation, driven by compelling mortality benefit: pembrolizumab demonstrated a hazard ratio of 0.62 (95% CI 0.44-0.87; p=0.005) for overall survival, alongside improved disease-free survival without deterioration in quality of life. 1
Treatment Protocol
- Dosing: Pembrolizumab 200 mg intravenously every 3 weeks for up to 17 cycles (approximately 1 year) 1, 2
- Eligible populations per KEYNOTE-564 criteria:
Your patient with T3/T4, N+, or grade 3-4 disease clearly falls within these criteria.
Critical Considerations Before Initiating Treatment
Toxicity Profile
While pembrolizumab improves survival, a significant proportion of patients experience life-changing or serious side effects that must be thoroughly discussed 1. Real-world data shows:
- Grade ≥3 adverse events occur in approximately 31-32% of patients 4, 5
- Treatment discontinuation is not uncommon (approximately 38% in real-world settings) 5
- Most common grade 3-4 events: hypertension (3%), elevated ALT (2%) 2
- Serious immune-related adverse events occurred in 12% of patients 2
Patient Selection Nuances
The absolute benefit of pembrolizumab appears risk-dependent, with greater absolute benefit in patients at higher baseline recurrence risk 6. However, even within KEYNOTE-564-eligible populations, baseline risk varies substantially. Consider:
- Patients with very high-risk features (T4, N+, sarcomatoid differentiation, necrosis) derive clearer benefit
- Lower-risk eligible patients may have more modest absolute benefit despite meeting enrollment criteria 6
What NOT to Do After Pembrolizumab
If disease recurs during or shortly after adjuvant pembrolizumab, do NOT rechallenge with PD-1/PD-L1 immune checkpoint inhibitors (either as monotherapy or combination therapy). 1 The TiNivo and CONTACT-03 trials in the metastatic setting do not support ICI rechallenge after progression on ICI therapy. Instead, transition to VEGFR-targeted therapy as the standard of care for post-ICI progression. 3
Common Pitfalls to Avoid
Overtreatment: Not all KEYNOTE-564-eligible patients have equal recurrence risk. Patients with isolated pT3a disease and favorable features may have lower absolute benefit compared to those with N+ or T4 disease 6
Inadequate informed consent: The 16% rate of serious immune-related adverse events requires explicit discussion about potential life-altering toxicities 6
Timing errors: Pembrolizumab should be initiated within 12 weeks of nephrectomy per trial protocol 1, 2
Contraindications ignored: Active autoimmune disease or conditions requiring systemic immunosuppression are relative contraindications that require careful consideration
Alternative Scenarios
If pembrolizumab is contraindicated or declined, surveillance remains the alternative, as no other adjuvant therapy has demonstrated survival benefit in this population. VEGFR-TKI agents (sunitinib, pazopanib) failed to show benefit in prior adjuvant trials and are not recommended. 7
The ESMO guidelines similarly endorse adjuvant pembrolizumab for oligometastatic M1 NED patients after complete resection 3, reinforcing the broad applicability of this recommendation across high-risk populations.